We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Arbutus Biopharma (ABUS - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Arbutus Biopharma is one of 1010 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 13.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ABUS has moved about 7% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.7% on a year-to-date basis. This means that Arbutus Biopharma is performing better than its sector in terms of year-to-date returns.
Aveanna Healthcare (AVAH - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 17.5%.
In Aveanna Healthcare's case, the consensus EPS estimate for the current year increased 420% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Arbutus Biopharma is a member of the Medical - Biomedical and Genetics industry, which includes 508 individual companies and currently sits at #67 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that ABUS is performing better in terms of year-to-date returns.
Aveanna Healthcare, however, belongs to the Medical - Outpatient and Home Healthcare industry. Currently, this 18-stock industry is ranked #52. The industry has moved +3.6% so far this year.
Investors with an interest in Medical stocks should continue to track Arbutus Biopharma and Aveanna Healthcare. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Arbutus Biopharma (ABUS - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Arbutus Biopharma is one of 1010 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 13.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ABUS has moved about 7% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.7% on a year-to-date basis. This means that Arbutus Biopharma is performing better than its sector in terms of year-to-date returns.
Aveanna Healthcare (AVAH - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 17.5%.
In Aveanna Healthcare's case, the consensus EPS estimate for the current year increased 420% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Arbutus Biopharma is a member of the Medical - Biomedical and Genetics industry, which includes 508 individual companies and currently sits at #67 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that ABUS is performing better in terms of year-to-date returns.
Aveanna Healthcare, however, belongs to the Medical - Outpatient and Home Healthcare industry. Currently, this 18-stock industry is ranked #52. The industry has moved +3.6% so far this year.
Investors with an interest in Medical stocks should continue to track Arbutus Biopharma and Aveanna Healthcare. These stocks will be looking to continue their solid performance.